You are here: Industry Insights > Ionis

News List

Aro Biotherapeutics signs licensing agreement worth up to $1.4bn pharmaceutical-technology
January 13, 2020
Aro Biotherapeutics, a biotech firm engaged in the development of protein biologics called Centyrins, has signed a licencing deal that can potentially generate up to $1.4bn for the company.
Ionis Licenses Investigational Alzheimer's Therapy americanpharmaceuticalreview
December 23, 2019
Ionis Pharmaceuticals announced Biogen, a collaboration partner for neurological diseases, has licensed IONIS-MAPTRx, an antisense therapy designed to selectively reduce production ...
Akcea Announces CEO Transition, Elects Two New Board Members americanpharmaceuticalreview
September 24, 2019
Akcea Therapeutics, a majority-owned affiliate of Ionis Pharmaceuticals, announced its board of directors has appointed Damien McDevitt, Ph.D., a member of its board of directors ...
Ionis Licenses Hepatitis B Program to GSK contractpharma
August 28, 2019
Transaction provides Ionis with significant participation in the commercial success of HBV program.
Ionis Announces Board of Directors Appointment americanpharmaceuticalreview
June 14, 2019
Ionis Pharmaceuticals announced the appointment of a new member to its board of directors effective immediately – Joan E. Herman, MBA, MS, president and chief executive officer of Herman and Associates.
Rejected by the FDA, Ionis and Akcea's Waylivra finds new life with EU approval fiercepharma
May 09, 2019
With its chances for an FDA approval dead in the water, Ionis and Akcea’s ultrarare lipid disorder treatment Waylivra seemed doomed. Fortunately, the drug found new life in Europe.
Novartis exercises rights to Ionis’ CV drug TQJ230 pharmaceutical-technology
February 26, 2019
Swiss pharmaceutical giant Novartis has announced it has exercised the option to license its right to develop and commercialise TQJ230, a targeted cardiovascular (CV) therapy....
U.K. cost watchdog NICE issues preliminary ‘no’ on Alnylam’s Onpattro and Ionis’ Tegsedi fiercepharma
December 14, 2018
Alnylam and Ionis are in a head-to-head battle for market share with their new treatments for the rare disease hereditary transthyretin-mediated amyloidosis (ATTR)...
Eyeing Novartis deal, Akcea trumpets lipoprotein drug data pharmaphorum
December 11, 2018
Ionis affiliate Akcea Pharma has new data for its antisense drug for elevated lipoprotein levels in patients with cardiovascular disease that it hopes will entice Novartis into a licensing deal......
Biogen Exercises Option with Ionis to Develop and Commercialize Investigational Treatment for a Subtype of ALS americanpharmaceuticalreview
December 10, 2018
Biogen Inc and Ionis Pharmaceuticals, Inc. have announced that Biogen exercised its option to obtain from Ionis a worldwide, exclusive, royalty-bearing license to.....

Previous page 1 2 3 Next page